KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Enterprise Value (2016 - 2025)

Teva Pharmaceutical Industries' Enterprise Value history spans 17 years, with the latest figure at -$3.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 20.14% year-over-year to -$3.6 billion, compared with a TTM value of -$3.6 billion through Dec 2025, down 20.14%, and an annual FY2025 reading of -$3.6 billion, down 20.14% over the prior year.
  • Enterprise Value for Q4 2025 was -$3.6 billion at Teva Pharmaceutical Industries, down from -$2.2 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$768.0 million in Q1 2021, with the low at -$3.6 billion in Q4 2025.
  • Average Enterprise Value over 5 years is -$2.0 billion, with a median of -$1.8 billion recorded in 2022.
  • Year-over-year, Enterprise Value plummeted 95.83% in 2024 and then soared 38.0% in 2025.
  • Tracing TEVA's Enterprise Value over 5 years: stood at -$1.2 billion in 2021, then crashed by 67.39% to -$2.0 billion in 2022, then crashed by 60.74% to -$3.2 billion in 2023, then grew by 8.25% to -$3.0 billion in 2024, then fell by 20.14% to -$3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Enterprise Value are -$3.6 billion (Q4 2025), -$2.2 billion (Q3 2025), and -$2.2 billion (Q2 2025).